Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Reseña (Review)

Targeting Viral Transcription for HIV Cure Strategies

  • Izquierdo-Pujol, Jon|||0000-0002-5903-9909
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Moron-Lopez, Sara|||0000-0003-0800-9205
Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa|||0000-0002-8202-6751
  • Ayllon-Hermida, Alberto|||0000-0002-9566-6934
  • Cortés Serra, Núria|||0000-0001-5396-3757
  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Aparici-Herraiz, Iris|||0000-0002-6014-8221
  • Nicolau Fernández, Marc|||0000-0001-7211-796X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Gutierrez-Chamorro, Lucia
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester|||0000-0002-5215-7363
  • Urrea, Víctor|||0000-0002-2577-856X
  • Fraile, Lorenzo|||0000-0002-8980-5862
  • Montoya, Maria|||0000-0002-5703-7360
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Fernandez-Becerra, Carmen|||0000-0001-5154-0013
  • De La Torre, Carolina
  • Pinazo, Maria-Jesus|||0000-0002-4237-1075
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Del Portillo, Hernando A.|||0000-0002-5278-3452
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound

  • Resa-Infante, Patricia
  • Piñol, Patricia
  • Laguía, Fernando
  • Campos-Gonzalez, Gerard
  • Cobos, Àlex
  • Urrea, Victor
  • Garcia-Guerrero, Maria del Carmen
  • Rosales-Salgado, Yaiza
  • Cid, Marina
  • Díaz-Pedroza, Jorge
  • Shultz, Leonard D
  • Yin, Voot
  • Brehm, Michael A.
  • Soper, Brian
  • Salgado, María
  • Martinez-Picado, Javier
Despite advances in antiretroviral therapy (ART), HIV-1 cure efforts remain hindered by viral persistence in long-lived myeloid cells and immune-privileged tissues that are poorly accessible and therefore unlikely to be assessed in human clinical trials. Consequently, robust research platforms, such as immune-cell humanized mice, are needed to bridge preclinical and clinical HIV research. However, previously described humanized mouse models often show incomplete hematopoietic development, particularly showing low levels of NK or myeloid cells. Herein, we evaluate a humanized FLT3 mouse model that develops NK cells, myeloid progenitors, monocytes, and both conventional (cDCs) and plasmacytoid dendritic cells (pDCs), and assessed its capacity to support HIV-1 infection, persistence, and viral rebound. Human cord blood derived CD34+ hematopoietic stem cells (HSC) were engrafted in FLT3 (Hu-FLT3) and NSG (Hu-NSG) mouse strains for comparison. While Hu-NSG and Hu-FLT3 mice showed comparable human lymphocyte levels, the proportion of myeloid-enriched populations, including monocytes, pDCs and cDCs, was three-fold higher in Hu-FLT3 mice (16.2%) than in Hu-NSG mice (5.6%), and the proportion of NK cells was six-fold higher (12.8% vs. 1.9%). Both strains supported HIV-1 infection, maintained viral replication for 17 weeks in untreated animals, and had detectable proviral DNA in peripheral blood, bone marrow and spleen. Oral ART reduced plasma HIV-1 RNA to undetectable levels within four weeks in both strains. After treatment discontinuation, viral rebound occurred within three weeks and approached pre-ART levels, consistent with rebound kinetics observed after treatment interruption in people living with HIV (PLWH). Human immune cells and HIV-1 RNA were more abundant in tissues from Hu-FLT3 mice than in Hu-NSG mice. This study establishes Hu‑FLT3 mice as a novel, robust and accessible in vivo platform to investigate potential HIV cure and persistence‑targeting interventions with translational relevance to human therapeutic development thanks to the improved and more complete human immune repertoire in Hu-FLT3., The authors’ laboratories were supported by funding from the Spanish Ministry of Science and Innovation (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), Generalitat de Catalunya (CERCA program and 2021-SGR-00452) NIH/NIAID (1UM1AI164561-01 and 1P01AI178376-01, United States of America), and Grifols (Spain). FL and GC-G were supported by PhD fellowships (PRE2020-095004 and PRE2021-100501, respectively) from Spanish Ministry of Science and Innovation. MS was supported by the Miguel Servet Fellowship Program (CP22/00038) and I+D+I Grant (PID2023-147320OB-I00) from the Spanish Ministry of Science and Innovation. MAB and LDS were supported by funding from NIH (R24OD036199) and by the Barbara D. Cammett Breakthrough T1D Center of Excellence in New England of the Breakthrough T1D Foundation (4-COE-2025-1751-A-N)., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.